The Global Market for Acute Heart Failure (AHF) Therapeutics is Projected to Reach US$1.2 Billion by 2022
New Drugs in the Pipeline to Drive the Market for Acute
Heart Failure (AHF) Therapeutics, According to a New Report by Global Industry Analysts, Inc.
GIA launches comprehensive
analysis of industry segments, trends, growth drivers, market size, share and
demand forecasts on the global Acute Heart Failure (AHF) Therapeutics market. The global market for Acute Heart Failure (AHF)
Therapeutics is projected to reach US$1.2 billion by 2022, driven by the expected launch of new therapies and spurt
in the incidence and prevalence of AHF largely due to the aging population.
Acute heart failure (AHF) has
emerged as a serious health problem, affecting particularly the elderly, and is
the major cause of hospitalization and death. AHF is a medical condition
characterized by tissue hypoperfusion, tissue congestion, lowered cardiac
output and higher pulmonary capillary wedge pressure/PCWP. High in-hospital
mortality and frequent re-hospitalization typify the condition. Therapeutic
management of AHF aims at improving symptomatic conditions such as peripheral
edema, tissue congestion and dyspnea. Conventional therapies of loop diuretics
and vasodilators, which have remained largely unchanged for decades, currently dominate
the market. Diuretic represents the basis or gold standard for acute heart
failure therapy, and is considered the first-line therapy for AHF, which aid in
removal of volume and decongestion. Vasodilators,
on the other hand, are recommended for use in AHF patients as an adjunctive
therapy to diuretics in hypertensive or normotensive patients for quick relief
from congestive symptoms. Limited efficacy of existing medications and lack of
novel effective medications leave significant unmet needs in the market.
Additionally, aging population and growing incidence and prevalence of acute
heart failure, which are the major drivers of market growth, are pushing the
need for more effective therapies.
New therapies are under
development to provide better AHF management, with a focus on near-term
improvements in dyspnea and reduction of CV related and overall mortality. Recombinant
biological drugs represent the new and promising approach to AHF therapy, with
Novartis’ Serelaxin and Cardiorentis’ Urodilatin representing the most
immediate and promising prospects based on their promising Phase 2 trial data. However,
the first in class products both faced their own share of troubles during their
development, with Serelaxin once rejected by both FDA and EMA, while Urodilatin,
a natriuretic peptide, failed to show desired efficacy in its phase III trials. Launch of
new and effective therapies, which are likely to be sold at higher prices, are
expected to invigorate growth in the market in the coming years.
As stated by the new
market research report on Acute Heart Failure (AHF) Therapeutics, Japan represents the largest market worldwide. Aging
society, high prevalence of heart failure cases, and higher adoption of AHF
therapeutics put Japan at the forefront of the global AHF therapeutics market. The
United States represents the fastest growing market worldwide, with a CAGR of
47.3% through the analysis period.
Major players covered in
the report include Bayer AG, Bristol-Myers Squibb Company, Cardiorentis AG,
CVie Therapeutics Limited, Cytokinetics Inc., Merck & Co., Novartis AG,
Orion Corporation and PhaseBio Pharmaceuticals Inc., among others.
The research report titled
“Acute Heart Failure (AHF) Therapeutics: A Global
Strategic Business Report” announced
by Global Industry Analysts Inc., provides a comprehensive review of market trends, issues, drivers, mergers,
acquisitions and other strategic industry activities of global companies. The
report provides market estimates and projections for Acute Heart Failure (AHF)
Therapeutics in value terms for all major geographic markets such as US, Japan,
Europe (France, Germany, Italy, UK, Spain and Rest of Europe) and Rest of World.
Global Industry Analysts, Inc. 6150 Hellyer Ave., San Jose CA 95138, USA,
All Rights Reserved.
Comments
Post a Comment